Zevra Therapeutics (ZVRA) – Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Zevra Therapeutics (NASDAQ: ZVRA) recently:

• 3/13/2025 – Zevra Therapeutics had its price target raised by analysts at Canaccord Genuity Group Inc. from $23.00 to $25.00. They now have a “buy” rating on the stock.
• 3/13/2025 – Zevra Therapeutics had its price target raised by analysts at Guggenheim from $20.00 to $22.00. They now have a “buy” rating on the stock.
• 3/13/2025 – Zevra Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
• 3/12/2025 – Zevra Therapeutics had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 3/12/2025 – Zevra Therapeutics was given a new $18.00 price target on by analysts at JMP Securities.
• 3/12/2025 – Zevra Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.
• 2/4/2025 – Zevra Therapeutics was given a new $21.00 price target on by analysts at Guggenheim. They now have a “buy” rating on the stock.
• 1/29/2025 – Zevra Therapeutics was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.

Zevra Therapeutics Trading Up 1.4 %

Shares of NASDAQ ZVRA opened at $7.96 on Friday. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The company’s fifty day moving average is $7.90 and its 200-day moving average is $8.19. The stock has a market cap of $430.76 million, a price-to-earnings ratio of -4.04 and a beta of 1.98. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. Equities research analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Activity

In other news, Director John B. Bode acquired 10,000 shares of Zevra Therapeutics stock in a transaction dated Wednesday, March 19th. The stock was bought at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $318,400. This represents a 33.33 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. The trade was a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock worth $674,176 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently made changes to their positions in ZVRA. Woodline Partners LP boosted its stake in shares of Zevra Therapeutics by 2.2% during the 4th quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock worth $34,524,000 after buying an additional 90,940 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Zevra Therapeutics by 462.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock valued at $30,441,000 after purchasing an additional 3,001,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Zevra Therapeutics by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock valued at $23,554,000 after buying an additional 68,151 shares in the last quarter. FMR LLC increased its stake in shares of Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after purchasing an additional 2,312,384 shares during the last quarter. Finally, Altium Capital Management LLC raised its stake in Zevra Therapeutics by 8.8% in the fourth quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock valued at $15,429,000 after buying an additional 150,000 shares during the period. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.